entertainment -WSS

entertainment

author：knowledge 2025-09-06 08:39:11 - browse：272

Jennifer Doudna Feng Zhang CRISPR — CRISPR pioneers Jennifer Doudna and Feng Zhang Illustration: STAT; Photos: AP, Getty

The revolution started in silence.

Jennifer Doudna and Emmanuelle Charpentier, now Nobelists, published their first paper announcing a new enzyme for editing DNA in Science in June 2012. It was called CRISPR-Cas9. It wasn’t until January 2013 that the first paper showing the enzyme would work in cells, from Feng Zhang, was published, also in Science. A similar paper from George Church came out at the same time.

No major media outlet covered the papers. The first story on CRISPR was published that March. But within the ivory tower of academia, it was clear something big was building, as requests for the technology poured in from other researchers and Zhang set up an assembly line in his laboratory to distribute it, with students carrying carefully packed samples to a FedEx office down the street.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： AI for drug discovery: Experts on separating hype from reality

WSS

Surgery pushed Ben Carson to fame

Surgery pushed Ben Carson to fame

AI gets buy

HHS's proposed rule does nothing to address the climate crisis

As billionaires fund anti

PBM executives asked to testify by House panel

hotspot

entertainment

focus

BioMarin wins approval for gene therapy to treat hemophilia A

Crowdfunding for medical bills sidesteps core problem, author says

Jerome Adams on the need for new antivirals for Covid

Empower primary care with adequate payments and technology

New air purifier tech could be key to improving indoor air quality

AstraZeneca stays mum on Medicare drug pricing negotiations

Dobbs anniversary: the lost opportunity of abortion as health care

As billionaires fund anti

Medical leaders decry Supreme Court decision on affirmative action

Top private equity targets in 2023: cardiology, clinical trials, lasers

focus

Brain MRIs reveal impact of 'toxic stress' on Black children

Welsh Carson private equity firm escapes from FTC antitrust case

Can gargling with Listerine treat gonorrhea of the mouth?

The CDC's new social media misinformation war

A protest over insulin prices is seen as a fight for life

Devoted Health’s losses in Medicare Advantage persist

Wikipedia

hotspot

entertainment

focus